Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Phase 4

Completed

Conditions: Attention-deficit/Hyperactivity Disorder

Interventions: Drug: Methylphenidate Hydrochloride
Drug: Placebo
Drug: Lisdexamfetamine dimesylate

Registration Number: NCT01552902

Lead Sponsor: Shire

Brief Summary: The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 549

Inclusion Criteria

Subject must be 13-17 years of age, inclusive, at the time of consent.
Subject must weigh more than 79.5lb.
The parent/LAR must be available at approximately 7:00AM (±2 hours) to dispense the dose of investigational product for the study duration.
Subject, who is a female, must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test and a negative urine pregnancy test and agree to comply with any applicable contraceptive requirements of the protocol.
Subject has an ADHD-RS-IV total score ≥28.
Subject is able to swallow a capsule.
Subject does not have hypertension and has a resting sitting blood pressure less than or equal to 135/85mmHg.

Exclusion Criteria

Subject has a current, controlled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as post traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, depressive or anxiety disorder.
Diagnosis of conduct disorder. Oppositional defiant disorder is not exclusionary.
Subject is considered a suicide risk, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded.
Subject is underweight or overweight.
Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition. Mild, stable asthma is not exclusionary.
Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place him/her at increased vulnerability to the sympathomimetic effects of a stimulant medication.
Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
Subject has any clinically significant ECG or clinically significant laboratory abnormality.
Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone (TSH) and thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.
Subject has a documented allergy, hypersensitivity, or intolerance to MPH or to any excipients in the reference product.
Subject has failed to fully respond to an adequate course(s) (dose and duration) of MPH or amphetamine therapy.
Subject has a history of suspected substance abuse or dependence disorder (excluding nicotine). Subjects with a lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded.
Subject has a positive urine drug result.
Subject has previously participated in this study or another clinical study involving SPD489/NRP104.
Subject has glaucoma.
Subject is required to take or anticipates the need to take medications that have CNS effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
Subject is female and is pregnant or lactating.
Subject is well controlled on his/her current ADHD medication.
Subject has a pre-existing severe gastrointestinal tract narrowing.

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Methylphenidate Hydrochloride	Methylphenidate Hydrochloride	-
Placebo	Placebo	-
Lisdexamfetamine dimesylate	Lisdexamfetamine dimesylate	-

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at Week 6	Baseline, Week 6	The ADHD-RS-IV was developed to measure the behaviors of children with ADHD and is commonly used in clinical studies of ADHD. The ADHD-RS-IV consisted of 18 items designed to reflect current symptomatology of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) criteria. Each item was scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54, Higher score = more severe symptoms.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With an Improvement on Clinical Global Impression - Global Improvement (CGI-I) at Week 6	Week 6	The Clinical Global Impressions Scale permits a global evaluation of the participant's severity of illness and improvement over time. The scale included a severity of illness item and a global improvement item. The investigator performed the CGI-I to rate the improvement of a participant's ADHD symptoms based on a 7-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse.). Percentage of participants with an improved measurement (response of very much improved and much improved) is reported.

Trial Locations

Locations (92): Harmonex Neuroscience Research, Inc.
🇺🇸
Dothan, Alabama, United States
Center for Advanced Improvement
🇺🇸
Tucson, Arizona, United States
Clinical Study Centers, LLC
🇺🇸
Little Rock, Arkansas, United States
Shanti Clinical Trials
🇺🇸
Colton, California, United States
Sun Valley Research Center
🇺🇸
Imperial, California, United States
Synergy Clinical Research Center
🇺🇸
National City, California, United States
Pacific Sleep Medicine, A Medical Corporation
🇺🇸
Oceanside, California, United States
Neuropsychiatric Research Center for Orange County
🇺🇸
Orange, California, United States
Peninsula Research Associates
🇺🇸
Rolling Hills Estates, California, United States
PCSD - Feighner Research
🇺🇸
San Diego, California, United States
Scroll for more (82 remaining)
Harmonex Neuroscience Research, Inc.
🇺🇸Dothan, Alabama, United States